U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07872553) titled 'A Study of Treatment Delivery Preference In People With Kidney Cancer' on Oct. 07.
Brief Summary: The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Study Start Date: Sept. 24
Study Type: INTERVENTIONAL
Condition:
Renal Cell Carcinoma
Kidney Cancer
Intervention:
DRUG: Nivolumab Injectable Product
Participants will be randomized to receive nivolumab subcutaneously
DRUG: Nivolumab
Participants...